Biosynthesis, Structure, and Function of Neuromelanin and its Relation to Parkinson's Disease: A Critical Update

Pigment Cell Research

Volumn 10, Issue 6, 1997, Pages 370-376

  D'Ischia, Marco ^a   Prota, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cysteinyldopamine; Dopamine; Extracutaneous melanins; Neuronal degeneration; Oxidative stress; Substantia nigra

Indexed keywords

MELANIN; NEUROMELANIN;

ANIMAL; BIOSYNTHESIS; CHEMISTRY; HUMAN; METABOLISM; PARKINSON DISEASE; PHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; MELANINS; PARKINSON DISEASE;

EID: 0031296810     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0749.1997.tb00694.x     Document Type: Review

References (69)

1. Aime, S., M. Fasano, B. Bergamasco, L. Lipiano, and G. Valente (1994) Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra. J. Neurochem., 62:369-371.
2. Aime, S., M. Fasano, B. Bergamasco, L. Lopiano, and G. Quattrocolo (1996) Nuclear magnetic resonance spectroscopy characterization and iron content determination of human mesencephalic neuromelanin. Adv. Neurol., 69, 263-270.
3. Barden, H. and K.R. Brizzee (1987) The histochemistry of lipofuscin and neuromelanin. In: Advances in Age Pigments Research. AlojTotaro, E.; Glees, P.; Pisanti, F.A., eds. Pergamon Press, Oxford, pp. 339-392.
4. Ben-Schachar, D., P. Riederer, and M.B.H. Youdim (1991) Iron-melanin interaction and lipid peroxidation: Implication for Parkinson's Disease. J. Neurochem., 57:1609-1614.
5. Braak, H. and E. Braak (1986) Nuclear configuration and neuronal types of the nucleus niger in the brain of the human adult. Human Neurobiol., 5:71-82.
6. Carlsson, A. and B. Fornstedt (1991) Possible mechanism underlying the special vulnerability of dopaminergic neurons. Acta Neurol. Scand., 84:16-18.
7. Carstam, R., C. Brinck, A. Hindemith-Augustsson, H. Rorsman, and E. Rosengren (1991) The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta, 1097:152-160.
8. Crippa, R., Q.J. Wang, M. Eisner, S.C. Moss, L. Zecca, P Zschack, and T. Gog (1996) Structure of human neuromelanin by X-ray diffraction: Comparison with synthetics. Pigment Cell Res., 5:72.
9. D'Amato, R.J., G.M. Alexander, R.J. Schwartzman, C.A. Kitt, D.L. Price, and S.H. Snyder (1987) Evidence for nouromelanin involvement in MPTP-induced neurotoxicity. Nature, 327:324-326.
10. D'Amato, R.J., D.F. Benham, and S.H. Snyder (1987) Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem., 48:653-658.
11. Damier, P., E.C. Hirsch, P. Zhang, Y. Agid, and F. Javoy-Agid (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience, 52:1-6.
12. d'Ischia, M. and C. Costantini (1995) Nitric oxide-induced nitration of catecholamine neurotransmitters: A key to neuronal degeneration? Bioorg. Med. Chem., 3:923-927.
13. Enochs, W.S., M.J. Nilges, and H.M. Swartz (1993) Purified human neuromelanin, synthetic dopamine as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J. Neurochem., 61:68-71.
14. Enochs, W.S., T. Sarna, L. Zecca, P.A. Riley, and H.M. Swartz (1994) The role of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's Disease: A hypothesis. J. Neural. Trans. Park. Dis. Dement. Sect., 7:83-100.
15. Fahn, S., and G. Cohen (1992) The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol., 32, 804-812.
16. Faraldi, F., M.G. Reyes, E. Alfieri, and A.C. Levi (1994) The aging substantia nigra: quantitative histologic study. Panminerva Med., 36:103-108.
17. Fornstedt, B. and A. Carlsson (1991) Vitamin C deficiency facilitates 5-S-cysteinyldopamine formation in guinea pig striatum. J. Neurochem., 56:407-414.
18. Fornstedt, B., E. Pileblad, and A. Carlsson (1990) In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem., 55:655-659.
19. Fornstedt, B., A. Brun, E. Rosengren, and A. Carlsson (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural. Trans. 1(P-D Sect):279-295.
20. Gerlach, M., A.X. Trautwein, L. Zecca, M.B.H. Youdim and E Riederer (1995) Mossbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J. Neurochem., 65:923-926.
21. Gibb, W.R.G. (1992) Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res. 581:283-291.
22. Gibb, W.R.G., and A.J. Lees (1991). Anatomy pigmentation, ventral and dorsal subpopulations of the substantia nigra is increased in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 54:388-396.
23. Grisham, M.B., V.J. Perez, and J. Everse (1987). Neuromelanogenic and cytotoxic properties of canine brainstem peroxidase. J. Neurochem. 48:876-882.
24. Hastings, T.G. (1995) Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J. Neurochem., 64:919-924.
25. Herrero, M.T., E.C. Hirsch, A. Kastner, M. Ruberg, M.R. Luquin, J. Laguna, F. Javoy-Agid, J.A. Obeso, and Y. Agid (1993) Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience, 56:499-511.
26. Hirsch, E.C. (1993) Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur. Neurol., 33:52-59.
27. Hirsch, E.C. (1994) Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol. Neurobiol., 9:135-142.
28. Jellinger, K., E. Kienzl, G. Rumpelmair, P. Riederer, H. Stachelberger, D. Ben-Schachar, and M.B.H. Youdim (1992) Iron-melanin complex in substantia nigra: Cause of Parkinson's disease. J. Neurochem., 59:1168-1171.
29. Jellinger, K., E. Kienzl, G. Rumpelmair, P. Riederer, H. Stachelberger, D. Ben-Schachar, and M.B.H. Youdim, and reply from Kastner, A.; E.C. Hirsch, F. Javoy-Agid, O. Lejeune, O. Rascol, Y. Agid (1993) Neuromelanin and nigrostriatal dopamine neuron degeneration. J. Neurochem., 60:1976-1977.
30. Jenner, P., A.H.V. Schapira, and C.D. Marsden (1992) New insights into the cause of Parkinson's disease. Neurology, 42:2241-2250.
31. Jenner, P., D. Dexter, J. Sian, A. Schapira, and C. Marsden (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol., 32:S82-S87.
32. Kastner, A., E.C. Hirsch, O. Lejeune, F. Javoy-Agid, O. Rascol, and Y. Agid (1992) Is the vulnerability of neurons in the Substantia Nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem., 59:1080-1089.
33. Korytowski, W., T. Sarna, and M. Zareba (1995) Antioxidant action of neuromelanin: The mechanism of inhibitory effect on lipid peroxidation. Archiv. Biochem. Biophys., 319:142-148.
34. Kropf, J., B. Bunker, L. Zecca, R. Crippa, S.C. Moss, and M. Eisner (1996) EXAFS studies of chelated Fe sites in natural and synthetic neuromelanins. Pigment Cell Res., 5:25.
35. Langston, J.W. (1989) Mechanisms underlying neuronal degeneration in Parkinson's disease: An experimental and theoretical treatise. Mov. Disord., 4:S15-S25.
36. Lindquist, N.G., B.S. Larsson, and A. Lydel-Sokolowski (1987) Neuromelanin and its possible protective and destructive properties. Pigment Cell Res., 1:133-136.
37. Linert, W., E. Herlinger, R.F. Jameson, E. Kienzl, K. Jellinger, and M.B.H. Youdim (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interaction and possible implication in the development of Parkinson's Disease. Biochim. Biophys. Acta, 1316:160-168.
38. Mann, D.M.A. and P.O. Yates (1974) Lipoprotein pigments: Their relationship to aging in the human nervous system. II. The melanin content of pigmented nerve cells. Brain, 97:489-498.
39. Mann, D.M.A. and P.O. Yates (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev., 21:193-203.
40. Marsden, C.D. (1983) Neuromelanin and Parkinson's disease. J. Neural Trans., 19S:121-141.
41. Mattammal, M.B., R. Strong, V.M. Lakshmi, D.C. Hyung, and A.H. Stephenson (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's Disease. J. Neurochem., 64:1645-1654.
42. Naoi, M., W. Maruyama, and P. Dostert (1994) Binding of 1,2(N)-di-methyl-6,7-dihydroxy-isoquinolinium ion to melanin: Effects of ferrous and ferric ion on the binding. Neurosci. Lett., 171:9-12.
43. Odh, G., R. Carstam, J. Paulson, A. Wittbjer, E. Rosengren, and H. Rorsman (1994) Neuromelanin of the human substantia nigra: A mixed-type melanin. J. Neurochem., 62:2030-2036.
44. Oestreicher, E., G.J. Sengstock, P. Riederer, C.W. Olanow, A.J. Dunn, and G.W Arendash (1994) Degeneration of nitrostriatal dopaminergic neurons increases iron within the Substantia Nigra: A histochemical and neurochemical study. Brain Res., 660:8-18.
45. Palumbo, A., M. d'Ischia, G. Misuraca, L. De Martino, and G. Prota (1995) Iron- and peroxide-dependent conjugation of dopamine with cysteine: Oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine. Biochim. Biophys. Acta, 1245:255-261.
46. Pezzella, A., M. d'Ischia, A. Napolitano, G. Misuraca, and G. Prota (1997) Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem., in press.
47. Prota, G. (1992) Melanins and Melanogenesis. Academic Press, San Diego, pp. 119-133.
48. Prota, G. and M. d'Ischia (1993). Neuromelanin: A key to Parkinson's disease. Pigment Cell Res., 6:333-335.
49. Rabey, J.M. and F. Hefti (1990) Neuromelanin synthesis in rat and human substantia nigra. J. Neural. Transm. Park. Dis. Dement. Sect., 2:1-14.
50. Riederer, P., E. Sofic, W.D. Rausch, B. Schmidt, G.P. Reynolds, K. Jellinger, and M.B.H. Youdim (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brain. J. Neuroehem., 52:515-520.
51. Rodgers, A.D. and G. Curzon (1975) Melanin formation by human brain in vitro. J. Neurochem., 24:1123-1129.
52. Rosei, M.A., C. Blarzino, C. Foppoli, L. Mosca, and R. Coccia (1994) Lipoxygenase-catalyzed oxidation of catecholamines. Biochem. Biophys. Res. Commun., 200:344-350.
53. Rosengren, E.E. Linder-Eliasson, and A. Carlsson (1985) Detection of 5-S-cysteinyldopamine in human brain. J. Neural Transmission, 63:247-253.
54. Shen, X.M., B. Xia, M.Z. Wrona, and G. Dryhurst (1996) Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: Possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol., 9:1117-1126.
55. Sian, J., D.T. Dexter, P. Jenner, and C.D. Marsden (1992) Glutathione-related enzymes in brain in basal ganglia degenerative disorders. Br. J. Pharmacol., 107:428P.
56. Sofic, E., W. Paulus, W. Jellinger, P. Riederer, and M.B.H. Youdim (1991) Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J. Neurochem., 56:978-982.
57. Spina, M.B. and G. Cohen (1989) Dopamine turnover and glutathione oxidation: implication for Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A., 86:1398-1400.
58. Temlett, J.A., J.P. Landsberg, F. Watt, and G.W. Grime (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: Evidence from proton microprobe elemental microanalysis. J. Neurochem., 62:134-146.
59. Wakamatsu, K., S. Ito, and T. Nagatsu (1991) Cysteinyldopamine is not incorporated into neuromelanin. Neurosci. Lett., 131:57-60.
60. Youdim, M.B.H., D. Ben-Schachar, and P. Riederer (1989) Is Parkinson's disease a progressive siderosis of Substantia Nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand., 126:47-54.
61. Youdim, M.B.H., D. Ben-Schachar, and P. Riederer (1993a) Iron-melanin interaction and Parkinson's disease. NIPS:45-19.
62. Youdim, M.B.H., D. Ben-Schachar, and E Riederer (1993b) The possible role of iron in the etiopathology of Parkinson's disease. Movement Disorders. 8:1-12.
63. Youdim, M.B.H., D. Ben-Schachar, and P. Riederer (1994) The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Transm., 43:113-122.
64. Zareba, M., A. Bober, W. Korytowski, L. Zecca, and T. Sarna (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochem. Biophys. Acta, 1271:343-848.
65. Zecca, L., C. Mecacci, R. Seraglia, and E. Parati (1992) The chemical characterisation of melanin contained in substantia nigra of human brain. Biochim. Biophys. Acta, 1138:6-10.
66. Zecca, L. and H.M. Swartz (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural. Trans. Park. Dis. Dement. Sect. 5:203-213.
67. Zecca, L., T. Shima, A. Stroppolo, C. Goj, G.A. Battiston, R. Gerbasi, T. Sarna, and H.M. Swartz (1996) Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience, 73:417-415.
68. Zhang, F.A. and G. Dryhurst (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: New reaction pathways of potential relevance to idiopathic Parkinson's Disease. J. Med. Chem., 37:1084-1098.
69. Zhang, F.A. and G. Dryhurst (1995) Reactions of cysteine and cysteinyl derivatives with dopamine-o-quinone and further insight into the oxidation chemistry of 5-S-cysteinyldopamine - potential relevance to idiopathic Parkinson's disease. Bioorg. Chem., 23:193-216.